Takeda Wants Japan, U.S. To Work Out Prevacid Taxing

Takeda Pharmaceutical is urging the Japanese and U.S. governments to determine which country alone will tax sales of its Prevacid (lansoprazole) ulcer drug. The drug maker already is involved in a 2006 dispute with competing taxing authorities in the two countries over the drug, which Takeda marketed at the time with TAP Pharmaceuticals of the United States. A Takeda subsidiary later absorbed TAP. Takeda's request involves all cross-border product transactions Takeda makes in the two countries. (Click here for more - a subscription may be required